Mostafa Ebrahimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mostafa Ebrahimi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ali Semati
Non‐communicable Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran
3 shared publications - Alireza Mirahmadizadeh
Non‐communicable Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran
3 shared publications - Marjan Zare
Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3 shared publications - Abdolrasool Hemmati
Department of Health Affairs Shiraz University of Medical Sciences Shiraz Iran
1 shared publication Abdulrasool Hemmati
Non-communicable diseases Research Centre, Shiraz University of Medical Sciences, Shiraz
1 shared publication- Ali Mohammad Mokhtari
Department of Epidemiology and Biostatistics, School of Health, Reproductive Health and Population Research Center, Gonabad University of Medical Sciences, Gonabad, Iran
1 shared publication
Latest Publications
- 23 June 2022
- Published by Wiley in Respirology
- Vol. 27 (9) , 758-766
Efficacy of single‐dose and double‐dose ivermectin early treatment in preventing progression to hospitalization in mild COVID‐19: A multi‐arm, parallel‐group randomized, double‐blind, placebo‐controlled trial
Background and objective: Ivermectin is a known anti‐parasitic agent that has been investigated as an antiviral agent against coronavirus disease 2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin in mild COVID‐19 patients.Methods: In this multi‐arm randomized clinical trial conducted between 9 April 2021 and 20 May 2021, a total of 393 patients with reverse transcription‐PCR‐confirmed COVID‐19 infection and mild symptoms were enrolled. Subjects were randomized in a 1:1:1 ratio to receive single‐dose ivermectin (12 mg), double‐dose ivermectin (24 mg) or placebo. The primary outcome was need for hospitalization.Results: There was no significant difference in the proportion of subjects who required hospitalization between the placebo and single‐dose ivermectin groups (absolute difference in the proportions: −2.3 [95% CI = −8.5, 4.1]) and between the placebo and double‐dose ivermectin groups (absolute difference in the proportions: −3.9 [95% CI = −9.8, 2.2]). The odds of differences in mean change in severity score between single‐dose ivermectin and placebo groups (ORdifference = 1.005 [95% CI: 0.972, 1.040]; p = 0.762) and double‐dose ivermectin and placebo groups (ORdifference = 1.010 [95% CI: 0.974, 1.046]; p = 0.598) were not statistically significant. None of the six adverse events (including mild dermatitis, tachycardia and hypertension) were serious and required extra action.Conclusion: Single‐dose and double‐dose ivermectin early treatment were not superior to the placebo in preventing progression to hospitalization and improving clinical course in mild COVID‐19.
- 23 June 2022
- Published by Wiley in Respirology
- Vol. 27 (9) , 758-766
Efficacy of single‐dose and double‐dose ivermectin early treatment in preventing progression to hospitalization in mild COVID‐19: A multi‐arm, parallel‐group randomized, double‐blind, placebo‐controlled trial
Background and objective: Ivermectin is a known anti‐parasitic agent that has been investigated as an antiviral agent against coronavirus disease 2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin in mild COVID‐19 patients.Methods: In this multi‐arm randomized clinical trial conducted between 9 April 2021 and 20 May 2021, a total of 393 patients with reverse transcription‐PCR‐confirmed COVID‐19 infection and mild symptoms were enrolled. Subjects were randomized in a 1:1:1 ratio to receive single‐dose ivermectin (12 mg), double‐dose ivermectin (24 mg) or placebo. The primary outcome was need for hospitalization.Results: There was no significant difference in the proportion of subjects who required hospitalization between the placebo and single‐dose ivermectin groups (absolute difference in the proportions: −2.3 [95% CI = −8.5, 4.1]) and between the placebo and double‐dose ivermectin groups (absolute difference in the proportions: −3.9 [95% CI = −9.8, 2.2]). The odds of differences in mean change in severity score between single‐dose ivermectin and placebo groups (ORdifference = 1.005 [95% CI: 0.972, 1.040]; p = 0.762) and double‐dose ivermectin and placebo groups (ORdifference = 1.010 [95% CI: 0.974, 1.046]; p = 0.598) were not statistically significant. None of the six adverse events (including mild dermatitis, tachycardia and hypertension) were serious and required extra action.Conclusion: Single‐dose and double‐dose ivermectin early treatment were not superior to the placebo in preventing progression to hospitalization and improving clinical course in mild COVID‐19.
- Open Access
- 30 May 2022
- Published by Hindawi Limited in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2022, 1-12
Spatiotemporal Study of COVID-19 in Fars Province, Iran, October-November 2020: Establishment of Early Warning System
Background. Using time series and spatiotemporal analyses, this study aimed to establish an Early Warning System (EWS) for COVID-19 in Fars province Iran. Methods. A EWS was conducted on (i) daily basis city-level time series data including 53 554 cases recorded during 18 February–30 September 2020, which were applied to forecast COVID-19 cases during 1 October–14 November 2020, and (ii) the spatiotemporal analysis, which was conducted on the forecasted cases to predict spatiotemporal outbreaks of COVID-19. Results. A total of 55 369 cases were forecasted during 1 October–14 November 2020, most of which (26.9%) occurred in Shiraz. In addition, 65.80% and 34.20% of the cases occurred in October and November, respectively. Four significant spatiotemporal outbreaks were predicted, with the Most Likely Cluster (MLC) occurring in ten cities during 2–22 October ( for all). Moreover, subgroup analysis demonstrated that Zarrindasht was the canon of the epidemic on 6 October ( ). As a part of EWS, the epidemic was triggered from Jahrom, involving the MLC districts in the center, west, and south parts of the province. Then, it showed a tendency to move towards Zarrindasht in the south and progress to Lar in the southernmost part. Afterwards, it simultaneously progressed to Fasa and Sepidan in the central and northwestern parts of the province, respectively. Conclusion. EWS, which was established based on the current protocol, alarmed policymakers and health managers on the progression of the epidemic and on where and when to implement medical facilities. These findings can be used to tailor province-level policies to servile the ongoing epidemic in the area; however, governmental level effort is needed to control the epidemic at a larger scale in the future.
- 30 May 2022
- Published by Hindawi Limited in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2022, 1-12
Open AccessSpatiotemporal Study of COVID-19 in Fars Province, Iran, October-November 2020: Establishment of Early Warning System
Background. Using time series and spatiotemporal analyses, this study aimed to establish an Early Warning System (EWS) for COVID-19 in Fars province Iran. Methods. A EWS was conducted on (i) daily basis city-level time series data including 53 554 cases recorded during 18 February–30 September 2020, which were applied to forecast COVID-19 cases during 1 October–14 November 2020, and (ii) the spatiotemporal analysis, which was conducted on the forecasted cases to predict spatiotemporal outbreaks of COVID-19. Results. A total of 55 369 cases were forecasted during 1 October–14 November 2020, most of which (26.9%) occurred in Shiraz. In addition, 65.80% and 34.20% of the cases occurred in October and November, respectively. Four significant spatiotemporal outbreaks were predicted, with the Most Likely Cluster (MLC) occurring in ten cities during 2–22 October ( for all). Moreover, subgroup analysis demonstrated that Zarrindasht was the canon of the epidemic on 6 October ( ). As a part of EWS, the epidemic was triggered from Jahrom, involving the MLC districts in the center, west, and south parts of the province. Then, it showed a tendency to move towards Zarrindasht in the south and progress to Lar in the southernmost part. Afterwards, it simultaneously progressed to Fasa and Sepidan in the central and northwestern parts of the province, respectively. Conclusion. EWS, which was established based on the current protocol, alarmed policymakers and health managers on the progression of the epidemic and on where and when to implement medical facilities. These findings can be used to tailor province-level policies to servile the ongoing epidemic in the area; however, governmental level effort is needed to control the epidemic at a larger scale in the future.
- Open Access
- 14 January 2022
- Published by PAGEPress Publications in Geospatial Health
- Vol. 17 (s1)
Spatial epidemiology and meteorological risk factors of COVID-19 in Fars Province, Iran
This study aimed at detecting space-time clusters of COVID-19 cases in Fars Province, Iran and at investigating their potential association with meteorological factors, such as temperature, precipitation and wind velocity. Time-series data including 53,554 infected people recorded in 26 cities from 18 February to 30 September 2020 together with 5876 meteorological records were subjected to the analysis. Applying a significance level of P<0.05, the analysis of space-time distribution of COVID-19 resulted in nine significant outbreaks within the study period. The most likely cluster occurred from 27 March to 13 July 2020 and contained 11% of the total cases with eight additional, secondary clusters. We found that the COVID-19 incidence rate was affected by high temperature (OR=1.64; 95% CI: 1.44-1.87), while precipitation and wind velocity had less effect (OR=0.84; 95% CI: 0.75-0.89 and OR=0.27; 95% CI: 0.14-0.51), respectively.
- 14 January 2022
- Published by PAGEPress Publications in Geospatial Health
- Vol. 17 (s1)
Open AccessSpatial epidemiology and meteorological risk factors of COVID-19 in Fars Province, Iran
This study aimed at detecting space-time clusters of COVID-19 cases in Fars Province, Iran and at investigating their potential association with meteorological factors, such as temperature, precipitation and wind velocity. Time-series data including 53,554 infected people recorded in 26 cities from 18 February to 30 September 2020 together with 5876 meteorological records were subjected to the analysis. Applying a significance level of P<0.05, the analysis of space-time distribution of COVID-19 resulted in nine significant outbreaks within the study period. The most likely cluster occurred from 27 March to 13 July 2020 and contained 11% of the total cases with eight additional, secondary clusters. We found that the COVID-19 incidence rate was affected by high temperature (OR=1.64; 95% CI: 1.44-1.87), while precipitation and wind velocity had less effect (OR=0.84; 95% CI: 0.75-0.89 and OR=0.27; 95% CI: 0.14-0.51), respectively.
- Open Access
- 1 November 2019
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 23 (6) , 419-426
The effectiveness of the national hepatitis B vaccination program 25 years after its introduction in Iran: a historical cohort study
- 1 November 2019
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 23 (6) , 419-426
Open AccessThe effectiveness of the national hepatitis B vaccination program 25 years after its introduction in Iran: a historical cohort study